Abstracts tagged "axial spondyloarthritis"

Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…
Abstract Number: 2774 • 2019 ACR/ARP Annual Meeting
Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort
Félicie Costantino ¹, Philippe Aegerter ², Anna Moltó ³, Georg Schett ⁴, Maxime Breban ⁵ and Maria-Antonietta D'Agostino⁶, ¹UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, ²Public Health Department - GIRCI IdF - INSERM/Versailles-Saint Quentin University, France, Versailles, France, ³Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁴Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁵UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, ⁶UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne Billancourt, France
Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial…
Abstract Number: 561 • 2019 ACR/ARP Annual Meeting
Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)
Eerik Ahomaa ¹, Uta Kiltz², Björn Bühring ³, Xenofon Baraliakos ⁴, Salima van weely ⁵ and Jürgen Braun ⁶, ¹Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Bochum, Germany, ²Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: In patients with axial spondyloarthritis (axSpA) physical functioning is frequently impaired. The current gold standard to assess physical functioning is self-reported questionnaires (i.e. BASFI),…
Abstract Number: 600 • 2019 ACR/ARP Annual Meeting
Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER)
Fabian Proft¹, Murat Torgutalp ², Anja Weiß ³, Mikhail Protopopov ⁴, Valeria Rios Rodriguez ⁵, Hildrun Haibel ¹, Kay-Geert Hermann ⁵, Christian Althoff ⁵, Olaf Behmer ⁶, Joachim Sieper ¹ and Denis Poddubnyy ⁷, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin, Berlin, Germany, ⁶Pfizer Inc., Berlin, Germany, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Disease flares in axial spondyloarthritis (axSpA) might occur even in patients with otherwise stable disease receiving effective anti-inflammatory therapy such as TNF inhibitors. The…
Abstract Number: 630 • 2019 ACR/ARP Annual Meeting
Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database
Vibeke Strand ¹, Atul Deodhar ², Philip G Conaghan ³, Isabelle Gilloteau ⁴, Olivia Massey ⁵, Haijun Tian ⁶, Aurore Yocolly ⁷, Nicola Booth⁵ and Rieke Alten ⁸, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Oregon Health & Science University, Portland, OR, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Product Lifecycle Services –NBS, Novartis Global Service Center, Dublin, Ireland, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Enthesitis is a major source of pain, functional impairment, and reduced health-related quality of life (HRQoL) in spondyloarthritis (SpA) patients; however, limited information is…
Abstract Number: 1431 • 2019 ACR/ARP Annual Meeting
Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
René-Marc Flipo¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille ⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Saannya Sequiera ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch ,Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The GO PRACTICE study was initiated following a demand by the French Health Authorities for long-term data on the real-life use of golimumab (GLM)…
Abstract Number: 1544 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Ariel Masetto ², Michelle Teo ³, Pauline Boulos ⁴, Dalton Sholter ⁵, Suneil Kapur ⁶, Emmanouil Rampakakis ⁷, Meagan Rachich ⁸, Odalis Asin-Milan ⁸, Allen Lehman ⁸ and Francois Nantel⁸, ¹Memorial University, Newfoundland, NL, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷JSS Medical Research, Montreal, Canada, ⁸Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous…
Abstract Number: 2775 • 2019 ACR/ARP Annual Meeting
Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort
Marion Pons ¹, Nathalie Costedoat-Chalumeau ², Karine Briot ³, Philippe Goupille ⁴, Christian Roux ⁵, Maxime Dougados ⁶ and Anna Moltó⁵, ¹Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, ²Cochin University Hospital, Paris, France, ³Rheumatology department, Cochin Hospital, Paris, France, Paris, Ile-de-France, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁶Cochin Hospital, Paris, France
Background/Purpose: Only scarce data is available on regarding pregnancy rates and pregnancy outcomes in early axial spondyloarthritis (axSpA). The objectives of this study were to…
Abstract Number: 562 • 2019 ACR/ARP Annual Meeting
Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis
Uta Kiltz¹, Robert B.M. Landewé ², Désirée van der Heijde ³, Martin Rudwaleit ⁴, Michael Weisman ⁵, Nurullah Akkoç ⁶, Annelies Boonen ⁷, Jan Brandt-Jürgens ⁸, Philippe Carron ⁹, Maxime Dougados ¹⁰, Laure Gossec ¹¹, Merryn Jongkees ¹², Pedro Machado ¹³, Helena Marzo-Ortega ¹⁴, Anna Molto ¹⁵, Victoria Navarro-Compán ¹⁶, Karin Niedermann-Schneider ¹⁷, Percival Degrava Sampaio-Barros ¹⁸, Gleb Slobodin ¹⁹, Filip Van den Bosch ⁹, Astrid van Tubergen ²⁰, Salima van weely ²¹, Dieter Wiek ²² and Jürgen Braun ²³, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ⁷Maastricht University Medical Center, Maastricht, Netherlands, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Ghent University Hospital, Ghent, Belgium, ¹⁰10Rheumatology B Department, Paris Descartes University, Cochin Hospital, Paris, France, ¹¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ¹²seaynmedical, Netherlands, Netherlands, ¹³Centre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, ¹⁵Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, ¹⁶University Hospital La Paz, IdiPaz, Madrid, Spain, ¹⁷ZHAW Gesundheit Institut für Physiotherapie, Winterthur, Switzerland, ¹⁸Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil, ¹⁹18Department of Internal Medicine A, Bnai Zion Medical Center, Technion, Haifa, Israel, ²⁰Maastricht University Medical Centre and Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands, ²¹Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ²²patient research partner, Germany, Germany, Germany, ²³Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: There is wide variation in the management of patients with axial spondyloarthritis (axSpA) worldwide with significant unmet needs such as delayed diagnosis. One way…
Abstract Number: 601 • 2019 ACR/ARP Annual Meeting
Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis – Data from the OptiRef Study
Fabian Proft¹, Laura Spiller ², Mikhail Protopopov ³, Valeria Rios Rodriguez ², Burkhard Muche ², Judith Rademacher ², Susanne Lüders ², Anne Katrin Weber ², Imke Redeker ⁴ and Denis Poddubnyy ⁵, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ²Charité Universitätsmedizin, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: One of the major reasons for a long diagnostic delay in axial spondyloarthritis (axSpA) is the late referral of patients by primary care physicians…
Abstract Number: 635 • 2019 ACR/ARP Annual Meeting
Association Between Radiographic Progression and Cardiovascular Risk in Spondyloarthritis: Data from CoSpaR REGISTRY
María Lourdes Ladehesa-Pineda¹, Maria Carmen Castro ², Ignacio Gomez-Garcia ², Pedro Seguí-Azpilcueta ³, María del carmen ábalos-Aguilera ⁴, Rocío Segura-Ruiz ⁵, Rafaela Ortega ², Laura Bautista-Aguilar ⁶, Inmaculada Aranda-Varela ⁷, Clementina López-Medina ⁸, Juan Luis Garrido-Castro ⁹, Chary Lopez-Pedrera ², Alejandro Escudero-Contreras ⁷, Eduardo Collantes-Estévez ⁷ and Yolanda Jiménez-Gómez ⁴, ¹Universitary Hospital Reina Sofia of Cordoba/University of Cordoba/IMIBIC, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Universitary Hospital Reina Sofía of Córdoba, Córdoba, Spain, ⁴IMIBIC, Córdoba, Spain, ⁵Reina Sofia University Hospital/IMIBIC, Córdoba, Spain, ⁶[email protected], Córdoba, Spain, ⁷Universitary Hospital Reina Sofía of Córdoba/University of Córdoba/IMIBIC, Córdoba, Spain, ⁸Cochin Hospital, Rheumatology Department, Paris, France, ⁹University of Córdoba, Córdoba, Spain
Background/Purpose: Our objectives are:To analyze the prevalence of comorbidities related to CV risk in a register of patients with spondyloarthritis (CoSpaR).To evaluate if there is…
Abstract Number: 1478 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials
Damien Roche¹, Martin Badard ¹, Laurent Boyer ², Pierre Lafforgue ¹ and Thao Pham ¹, ¹Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²Aix-Marseille University, EA 3279 Research Unit, 13,000 Marseille, France, Marseille, France
Background/Purpose: Inflammatory bowel diseases (IBD) and anterior uveitis (AU) are frequent extra-articular features of axial spondyloarthritis (axSpA). Although effect of anti-TNF on IBD and AU…
Abstract Number: 1546 • 2019 ACR/ARP Annual Meeting
Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
Ennio Giulio Favalli ¹, Antonio Marchesoni ¹, Silvia Balduzzi ², Carlomaurizio Montecucco ³, Claudia Lomater ⁴, Gloria Crepaldi ⁴, Silvia Tamanini ⁵, Chiara Bazzani ⁶, Enrico Fusaro ⁷, Marta Priora ⁷, Aurora Ianniello ⁸ and Roberto Caporali¹, ¹University of Milan, Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ²Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Lombardia, Italy, ³Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁴AO Ordine Mauriziano, SSD Reumatologia, Torino, Turin, Piemonte, Italy, ⁵ASST Spedali Civili and University of Brescia, Milan, Lombardia, Italy, ⁶Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁷A.O.U. Città della Salute e della Scienza di Torino, SC Reumatologia, Turin, Piemonte, Italy, ⁸Day Hospital Multidisciplinare PO SS. Trinità, Borgomanero, Borgomanero, Piemonte, Italy
Background/Purpose: Observational data on the use of secukinumab for the treatment of spondyloarthritides are still lacking. The aim of this study is to evaluate the…
Abstract Number: 2776 • 2019 ACR/ARP Annual Meeting
5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort
Marion Pons ¹, Sylvie Chevret ², Karine Briot ¹, Maria-Antonietta D’Agostino ³, Christian Roux ⁴, Maxime Dougados ⁵ and Anna Moltó⁴, ¹Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, ²INSERM U-1153, CRESS Paris-Sorbonne, Paris, Paris, Ile-de-France, France, ³Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France, ⁴Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁵Cochin Hospital, Paris, France
Background/Purpose: Only scarce date is available on the long term treatment effect in a real-life setting (i.e. effectiveness) of TNFi in early axial SpA forms…
Abstract Number: 563 • 2019 ACR/ARP Annual Meeting
The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study
Rikke Andreasen¹, Lars Erik Kristensen ², Kenneth Egstrup ¹, Xenofon Baraliakos ³, Vibeke Strand ⁴, Hans Christian Horn ⁵, Inger Marie Hansen ¹, Robin Christensen ⁶ and Torkell Ellingsen ⁷, ¹Odense University Hospital, Svendborg, Svendborg, Denmark, ²Musculoskeletal Statistics Unit, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany, Herne, Germany, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁵Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark, Odense, Denmark, ⁶Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital & Department of Rheumatology, Institute of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark
Background/Purpose: To explore the impact of sex and disease classification on outcomes in axial spondyloarthritis (axSpA) patients, including both ankylosing spondylitis (AS) and non-radiographic (nr-)…

« Previous Page
1
…
3
4
5
6
7
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].